Vitamin C

For general health in healthy adults, 200-500 mg daily is a well-evidenced target: above the RDA (90 mg men, 75 mg women) to provide margin for oxidative stress and occasional suboptimal intake, but below the point where GI tolerance becomes an issue and diminishing returns dominate. Smokers should add ~35 mg/day due to increased turnover. During acute viral illness or high-stress periods, increasing to 1,000-2,000 mg daily split into divided doses (e.g., 500 mg QID) is reasonable for the duration of illness based on Hemilä's common cold meta-analyses (PMID 23440782). For specific clinical targets (wound healing, post-op recovery, chronic disease adjunct), 500-1,000 mg daily is typical. Chronic doses above 2,000 mg/day provide minimal systemic benefit because oral absorption saturates around 200-400 mg per single dose and plasma concentration plateaus around 80 μmol/L at intakes of 400 mg/day (Levine et al., PMID 8618259). For most users, 500 mg once or twice daily with meals is the evidence-based sweet spot.

Yes, modestly and consistently, with some nuance by population and dose. The Cochrane meta-analysis by Hemilä and Chalker (PMID 23440782) pooled 29 trial comparisons with 11,306 participants and found regular prophylactic vitamin C supplementation (≥200 mg/day): (1) did not meaningfully reduce cold incidence in the general population, but (2) reduced cold duration by 8% in adults and 14% in children, and (3) reduced cold incidence by about 50% in populations under heavy physical stress (marathon runners, soldiers, skiers). Therapeutic dosing started at cold onset shows smaller and less consistent effects than prophylactic daily dosing. Practical recommendations: 500-1,000 mg daily as prophylaxis through cold/flu season, increased to 1,000-2,000 mg daily split across 2-4 doses at first sign of symptoms through resolution. Don't expect dramatic effects—a 24-hour reduction in a 5-day cold is typical—but effects are real, reliable, and cheap.

The claims exceed the evidence. Liposomal vitamin C packages ascorbic acid in phospholipid vesicles to theoretically enhance intestinal absorption and plasma concentrations. Some studies (Davis et al., PMID 27434023) show modest plasma increases compared to equivalent oral ascorbic acid, but the differences are smaller than marketing often suggests, and no liposomal formulation can exceed the pharmacokinetic ceiling that IV administration reaches. For typical doses of 500-1,000 mg, plain ascorbic acid in divided doses produces essentially the same plasma AUC as liposomal at far lower cost. Liposomal may offer incremental benefit at higher oral doses (2+ g) where standard forms saturate more quickly, and may be worth considering for users pursuing aggressive oral protocols who cannot access IV. For general supplementation, the $30-60/month cost of liposomal versus $5-15 for plain ascorbic acid is rarely justified. If you want pharmacologic plasma concentrations, you need IV; if you want nutritional optimization, plain forms in divided doses are fine.

In susceptible individuals at chronic high doses, yes—but the risk is manageable and moderate. Vitamin C is partially metabolized to oxalate, which combines with calcium to form calcium oxalate stones (the most common type). Thomas et al. (PMID 23381591) found men taking ≥1,000 mg/day vitamin C had a 43% increased risk of kidney stones versus non-users in the Cohort of Swedish Men. Women appear less susceptible. Practical guidance: (1) healthy adults with no stone history can safely take 500-1,000 mg/day indefinitely; (2) individuals with history of calcium oxalate stones should limit supplementation to ≤500 mg/day, hydrate to produce 2+ liters of urine daily, and discuss with their urologist/nephrologist; (3) buffered ascorbate forms (calcium, magnesium, sodium) do not meaningfully reduce oxalate production compared to ascorbic acid; (4) dietary vitamin C from fruits/vegetables has not been associated with increased stone risk and may actually be protective. The stone risk is a consideration for supplementation doses chronically above 1 g/day, particularly in men with prior stone history, and is manageable with dose moderation and hydration.

Yes for iron deficiency anemia; no for iron overload disorders. Vitamin C in the intestinal lumen reduces Fe³⁺ to Fe²⁺ and enhances non-heme iron absorption by 2-4×. For iron-deficiency anemia treatment with oral ferrous sulfate (or equivalent), co-administering 100-200 mg vitamin C with the iron + a meal substantially improves absorption and clinical response. This is one of the most practically useful vitamin C pairings outside of scurvy prevention. Recent research (Li et al., PMID 32207823) has questioned whether the enhancement is as clinically meaningful for some newer iron formulations, but for classic ferrous sulfate it remains robust. Vegetarians and vegans should routinely consume vitamin C-rich foods (citrus, peppers, berries) with plant-based iron sources (spinach, lentils, tofu) for the same reason. IMPORTANT EXCEPTION: individuals with hereditary hemochromatosis, thalassemia major, or transfusion-dependent iron overload should NOT take vitamin C supplements above RDA doses, as it worsens iron accumulation and organ damage.

At chronic high doses (≥1 g/day) during training blocks, possibly yes; at modest doses (≤500 mg/day), no. Ristow et al. (PMID 19433800) and Paulsen et al. (PMID 25176036) showed that chronic supplementation of vitamin C (1 g/day) and/or vitamin E during exercise training periods modestly blunted exercise-induced mitochondrial biogenesis and adaptations to endurance training. The mechanism is that exercise-induced reactive oxygen species serve as signals driving training adaptations, and excessive antioxidant buffering dampens the adaptive signal. Practical recommendation for serious athletes: (1) keep vitamin C intake around the 200-500 mg/day range during key training blocks; (2) reserve gram-level doses for acute illness, post-competition recovery, or short windows outside intense training; (3) get vitamin C primarily from whole food sources which deliver smaller doses with fewer concerns; (4) for recreational exercisers not optimizing peak performance, chronic 500-1,000 mg/day is unlikely to meaningfully affect outcomes. Athletes with documented deficiency are a different situation—repletion improves, not impairs, performance.

Possibly as adjunctive therapy in specific contexts, but not as monotherapy or primary treatment. The story evolved as follows: Pauling and Cameron's 1970s oral megadose work showed apparent benefits that weren't replicated in Moertel's RCT (PMID 3897010), leading to decades of dismissal. Pharmacokinetic clarification that oral vitamin C cannot achieve pharmacologic plasma concentrations because of absorption saturation (Padayatty et al., PMID 15068981) sparked a revival using IV administration to reach plasma levels >1 mM where pro-oxidant (tumor-killing) effects emerge. Contemporary trials combining IV vitamin C (25-75 g/infusion) with chemotherapy or radiation in pancreatic, ovarian, glioblastoma, and hematologic cancers show suggestive signals and quality-of-life improvements (Polireddy et al., PMID 28719591 reviews the field). Hard overall-survival data remain limited, and trials are ongoing. IV vitamin C is used in integrative oncology settings; it is not yet standard-of-care but is no longer dismissed as quackery when used as adjunct to conventional therapy under oncologist supervision. Pre-treatment G6PD and renal screening is mandatory. Do not replace standard cancer therapy with IV vitamin C monotherapy—the evidence does not support that.

Ester-C is a branded formulation of calcium ascorbate combined with vitamin C metabolites (primarily threonate). Marketing claims include gentler on the stomach, longer-lasting, and better retained by tissues. Some evidence (Moyad et al., PMID 18335459) suggests slightly improved leukocyte vitamin C retention with Ester-C versus ascorbic acid at equivalent doses. The clinical significance is modest; most users won't notice a meaningful difference. Ester-C is typically priced 2-3× higher than plain ascorbic acid. Reasonable choice for users with ascorbic acid GI intolerance who want a buffered form with added marketing pedigree; otherwise, plain ascorbic acid, sodium ascorbate, or calcium ascorbate at equivalent elemental vitamin C doses provide essentially equivalent outcomes at much lower cost. The buffered forms (Ester-C, calcium/sodium/magnesium ascorbate) are genuinely gentler on the stomach than plain acidic ascorbic acid, which is the main practical advantage.

Yes, quite easily, if the diet includes daily fruits and vegetables. Food sources of vitamin C include: red bell pepper raw (150 mg/cup), guava (200 mg each), kiwi (90 mg each), strawberries (85 mg/cup), orange (70 mg each), broccoli cooked (50 mg/half cup), cantaloupe (60 mg/cup), tomato (25 mg/medium), kale (90 mg/cup raw). Meeting the RDA (75-90 mg) from food is trivial with even modest fruit/vegetable consumption. Meeting 200-500 mg from food alone requires deliberate inclusion (e.g., 1 orange + 1 kiwi + 1/2 red pepper + serving of broccoli = 400+ mg) but is entirely achievable and delivers complementary flavonoids, carotenoids, fiber, and phytochemicals that isolated ascorbic acid lacks. For many users, the best approach is dietary emphasis + modest supplementation at 200-500 mg to cover days of lower intake and provide baseline assurance. Supplementation is cheap and safe; dietary intake provides the broader food-matrix benefits. Both approaches together are optimal.

Yes, particularly topically and when combined with oral collagen support. Vitamin C is required for collagen synthesis (via prolyl and lysyl hydroxylases), is an antioxidant protecting skin from photodamage, and supports fibroblast function. Oral supplementation at 500-1,000 mg daily supports systemic collagen synthesis alongside adequate protein and glycine intake (see /compound/glycine for the collagen-glycine connection). Topical vitamin C serums (15-20% L-ascorbic acid) applied AM under sunscreen provide direct dermal delivery not achievable orally; evidence for topical effects on photoaging, hyperpigmentation, and collagen synthesis in the dermis is solid (multiple RCTs over 6-12 months). Combined oral + topical approach is the evidence-based dermatological recommendation. Adjunct strategies include oral collagen peptides 10-15 g daily, adequate dietary protein (1.0-1.2 g/kg), sun protection (SPF 30+ daily), and retinoid use as tolerated. Don't expect dramatic reversal of established deep wrinkles from vitamin C alone, but steady improvement in skin tone, texture, and resilience over 3-6 months is a realistic expectation with consistent topical + oral protocols.